# Prosthetic Valve Endocarditis

Prosthetic valve endocarditis requires early culture-directed evaluation, transesophageal echocardiography, and selective CT or FDG-PET/CT to detect occult paravalvular infection and define urgency for valve surgery.

**Clinical question:** How should clinicians confirm prosthetic valve endocarditis, identify complications, and determine urgency of surgical management?

Updated: 2026-08-21T01:53:09.167874+00:00

## What matters in practice
- Obtain blood cultures before antibiotics and apply Duke-ISCVID clinical, microbiologic, and multimodality imaging criteria to suspected PVE.[3][13]
- Use TEE early in suspected PVE; serial echocardiographic comparison is particularly important because vegetations may be less apparent and paravalvular complications more common than in native-valve infection.[3]
- When echocardiography is nondiagnostic or paravalvular extension is suspected, cardiac CT and FDG-PET/CT can identify prosthetic-valve infection and abscess-related anatomy.[6][10][13]
- Escalate promptly to an endocarditis team and cardiac surgery for heart failure from prosthetic dysfunction, abscess or fistula, persistent sepsis, high embolic risk, or fungal or multiresistant infection.[2][22]
- PVE carries substantial mortality, estimated at 22% to 40% in contemporary series; MRSA PVE mortality estimates range from 40% to 80%.[23][24]

## Stabilize, culture, and classify before antimicrobial exposure

Treat suspected PVE as a potentially destructive infection requiring parallel diagnostic and surgical assessment.

Assess immediately for prosthetic dysfunction causing acute heart failure or cardiogenic shock, conduction disturbance suggesting annular extension, systemic embolic disease, and persistent bacteremia. Valve dysfunction causing refractory heart failure or cardiogenic shock, new heart block, annular or aortic abscess, and penetrating lesions are high-risk features that warrant urgent endocarditis-team and surgical involvement.[2]

Obtain blood cultures before starting antibiotics whenever clinical stability permits. Diagnostic classification should use the Duke-ISCVID framework, which integrates clinical findings, microbiology, echocardiography, cardiac CT, FDG-PET/CT, molecular microbiology, and intraoperative evidence.[3][13]

Do not exclude PVE after a nondiagnostic initial echocardiogram. Compared with native-valve endocarditis, PVE has fewer visible vegetations—particularly with mechanical valves—but more annular abscesses and paravalvular complications; serial imaging comparison therefore changes diagnostic confidence and operative planning.[3]
- Obtain infectious diseases and valve/endocarditis multidisciplinary input at presentation; ACC/AHA guidance identifies infectious diseases expertise as a core component of endocarditis management.[3]
- Reassess with repeat TEE and/or TTE when clinical signs change or when the patient is at high risk for complications.[5]

## Use multimodality imaging when TEE does not resolve prosthetic-valve infection

Imaging should answer two separate questions: is the prosthesis infected, and has infection extended beyond the valve?

Perform early TEE in suspected PVE because auscultation may be unrevealing and TTE can miss prosthetic-valve lesions. TEE remains central, but sensitivity is lower in PVE than in native-valve infection; compare serial studies rather than treating one negative examination as definitive.[3]

Escalate to cardiac CT when suspected paravalvular infection cannot be anatomically delineated by echocardiography. CT can establish pseudoaneurysm, intracardiac fistula, valve perforation or aneurysm, and other paravalvular lesions that affect the feasibility and extent of surgery.[6]

Use FDG-PET/CT as an adjunct when PVE remains possible after conventional assessment, particularly with complex implants. In a prospective cohort of suspected PVE, abnormal cardiac uptake had 73.6% sensitivity and 75% specificity for definite PVE; the 2023 Duke-ISCVID criteria incorporate FDG-PET/CT and cardiac CT among diagnostic modalities.[10][13]

*Imaging escalation in suspected prosthetic valve endocarditis.[3][6][10][13]*

| Clinical problem | Next imaging action | Decision consequence |
| --- | --- | --- |
| Initial suspected PVE | Early TEE; compare with prior and repeat studies when risk or clinical status changes.[3][5] | Detect vegetations, prosthetic dysfunction, dehiscence, and hemodynamic complications. |
| TEE equivocal or suspected annular/paravalvular extension | Cardiac CT for morphology and anatomy when echocardiography cannot define suspected paravalvular infection.[6] | Identify abscess-related anatomy, pseudoaneurysm, fistula, perforation, or aneurysm relevant to surgery. |
| Possible PVE despite unrevealing conventional testing or complex prosthetic material | FDG-PET/CT as an adjunctive imaging criterion; abnormal cardiac uptake supports PVE.[10][13] | Increase diagnostic certainty and identify occult cardiac infection. |

## Direct antimicrobial strategy by organism, resistance, and prosthetic material

Culture results and susceptibility testing should drive definitive therapy and the urgency of source control.

Staphylococci are the dominant PVE pathogens, accounting for approximately 40% of contemporary cases, with S. aureus the most common organism. Healthcare-associated infection is common in PVE and should heighten concern for S. aureus and resistant organisms.[24]

For MRSA or methicillin-resistant coagulase-negative staphylococcal PVE, published treatment recommendations have used vancomycin with rifampin plus an aminoglycoside, but the evidence base is largely expert opinion, animal data, and retrospective experience rather than large PVE trials.[7][8][23] Avoid presenting adjunctive rifampin or aminoglycoside therapy as risk-free: nephrotoxicity, drug interactions, and resistance selection require organism-specific infectious diseases oversight.

Complicated native-valve infection, PVE, and endocarditis complicated by osteomyelitis are generally treated for 6 weeks in the cited comparative-regimen review.[19] If blood cultures remain positive or the patient develops worsening heart failure, embolic events, conduction abnormalities, or enlarging lesions despite therapy, treat this as failure of medical control and re-evaluate urgently for surgery.[2][22]

*Microbiologic patterns that alter PVE management.[7][8][19][23][24]*

| Finding | Interpretation | Management implication |
| --- | --- | --- |
| S. aureus or coagulase-negative staphylococcal PVE | Staphylococci cause about 40% of PVE; S. aureus is the most common pathogen.[24] | Require susceptibility-directed intravenous therapy and early assessment for destructive infection or operative source control. |
| MRSA PVE | Mortality estimates range from 40% to 80%; historical recommendations use vancomycin with rifampin and an aminoglycoside.[7][23] | Use infectious diseases-directed therapy; assess renal toxicity and drug interactions while pursuing source control. |
| Fungal or multiresistant organism | These pathogens are associated with guideline-level surgical indications.[2] | Obtain urgent cardiac surgical assessment rather than relying on medical therapy alone. |
| PVE or other complicated endocarditis | A 6-week treatment duration is reported for PVE and complicated infection.[19] | Plan prolonged parenteral therapy with serial microbiologic and complication assessment. |

## Refer early for surgery when infection causes hemodynamic compromise, invasive extension, or uncontrolled sepsis

The operative decision is driven by heart failure, local invasion, failure of antimicrobial control, and embolic risk—not vegetation alone.

Surgery is indicated for prosthetic-valve dysfunction causing heart failure, severe acute regurgitation, obstruction, or fistula with refractory heart failure, cardiogenic shock, or poor hemodynamic tolerance. These are time-sensitive indications because waiting for antimicrobial completion can permit irreversible hemodynamic deterioration.[2]

Treat abscess, false aneurysm, fistula, enlarging vegetation, new conduction disease, or other locally uncontrolled infection as a surgical problem. PVE has a higher burden of annular abscess and paravalvular complications than native-valve infection, making CT and serial TEE useful for defining invasive anatomy.[2][3][6]

Persistent sepsis, acute renal failure, embolic events or high embolic risk, mobile or large lesions greater than 10 mm, and fungal or multiresistant infection are reported operative triggers in PVE reviews and guideline comparisons.[2][22] A multidisciplinary discussion should incorporate neurologic status, hemodynamic stability, prosthesis type, anatomic reconstruction requirements, and likelihood of durable infection control.
- In patients with injection drug use, do not withhold surgery solely because of substance use; cited guidance supports surgery for failed medical therapy, septic pulmonary emboli, and large vegetations, while incorporating addiction treatment and recurrence risk into longitudinal planning.[2]
- Expect high perioperative risk in complex PVE: reported adverse postoperative outcomes include embolization and acute renal failure at 21%, new dialysis at 20%, stroke at 13% to 19%, and reoperation for bleeding at 12% to 14%.[22]

*Findings that should trigger urgent endocarditis-team and cardiac-surgical review.[2][22]*

| Trigger | Evidence of failed control | Immediate next step |
| --- | --- | --- |
| Heart failure or shock | Severe acute regurgitation, obstruction, or fistula causing refractory heart failure, cardiogenic shock, or poor hemodynamic tolerance.[2] | Urgent surgical evaluation for prosthetic dysfunction. |
| Invasive perivalvular infection | Abscess, false aneurysm, fistula, enlarging vegetation, new heart block, or penetrating lesion.[2][22] | TEE plus cardiac CT to define extension; plan operative source control. |
| Persistent infection | Persistent sepsis despite antimicrobial therapy.[22] | Repeat cultures and imaging; expedite surgery assessment. |
| Embolic risk | Mobile or large lesion greater than 10 mm, embolic event, or high embolic risk.[22] | Assess timing of surgery with embolic and neurologic risk considered. |
| Difficult pathogen | Fungal or multiresistant organism.[2] | Urgent surgery and infectious diseases co-management. |

## Monitor for microbiologic clearance and delayed structural complications

PVE management remains dynamic until infection control and prosthetic function are both established.

Repeat TEE and/or TTE when symptoms or signs change and in patients at high risk for complications. Compare studies for enlarging vegetation, worsening regurgitation or obstruction, new dehiscence, and newly visible paravalvular extension; serial imaging has particular value in PVE because the initial TEE may be falsely reassuring.[3][5]

Follow the patient for new heart failure, cardiogenic shock, atrioventricular conduction disease, embolic events, and persistent sepsis, each of which changes the surgical urgency. Contemporary PVE mortality is estimated at 22% to 40%, supporting close inpatient reassessment rather than a static antibiotic-only plan.[2][24]

If the patient has a prosthetic valve and infective endocarditis with neurologic complications, one CHEST guideline suggests holding vitamin K antagonist therapy until the patient is stabilized without neurologic complications. Anticoagulation decisions require individualized coordination among cardiology, neurology, infectious diseases, and cardiac surgery because thrombotic and hemorrhagic risks can compete.[20]

## References
1. Infective endocarditis — www.thelancet.com — https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)15266-X/fulltext
2. Diagnosis and Management of Infective Endocarditis in People Who Inject Drugs: JACC State-of-the-Art Review — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2022.03.349
3. 2020 ACC/AHA Guideline for the Management of Patients ... — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2020.11.018
4. ACC/AHA Versus ESC Guidelines on Prosthetic Heart Valve Management: JACC Guideline Comparison — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2019.01.038
5. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines — www.jacc.org — https://www.jacc.org/doi/10.1016/j.jacc.2014.02.537
6. Multimodality Imaging in Infective Endocarditis — www.ahajournals.org — https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.119.040228
7. Staphylococcus epidermidis Causing Prosthetic Valve ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-98-4-447
8. Combination Antimicrobial Therapy for Staphylococcus ... — www.acpjournals.org — https://www.acpjournals.org/doi/10.7326/0003-4819-97-4-496
9. [18F]FDG-PET CT for the evaluation of native valve endocarditis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1071358123001812
10. Comparison Between ESC and Duke Criteria for the Diagnosis of Prosthetic Valve Infective Endocarditis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1936878X20303351
11. Correlating cardiac F-18 FDG PET/CT results with intra-operative findings in infectious endocarditis - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S1071358123007705
12. 18F-FDG PET/CT improves diagnostic certainty in native and prosthetic valve Infective Endocarditis over the modified Duke Criteria - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1071358123005330
13. 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: Updating the Modified Duke Criteria | Clinical Infectious Diseases | Oxford Academic — academic.oup.com — https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciad271/7151107?redirectedFrom=fulltext
14. Infective Endocarditis : Advanced Emergency Nursing Journal — journals.lww.com — https://journals.lww.com/aenjournal/fulltext/2003/04000/infective_endocarditis.6.aspx
15. New agents for Staphylococcus aureus endocarditis — journals.lww.com — https://journals.lww.com/co-infectiousdiseases/fulltext/2006/12000/new_agents_for_staphylococcus_aureus_endocarditis.4.aspx
16. Abstracts : Journal of Clinical Infectious Disease Society — journals.lww.com — https://journals.lww.com/cids/fulltext/2025/07000/abstracts.10.aspx
17. Abstracts at CIDSCON 2024 : Journal of Clinical Infectious ... — journals.lww.com — https://journals.lww.com/cids/fulltext/2024/02030/abstracts_at_cidscon_2024.13.aspx
18. Clinical Guidance for Acute Rheumatic Fever | Group A Strep | CDC — www.cdc.gov — https://www.cdc.gov/group-a-strep/hcp/clinical-guidance/acute-rheumatic-fever.html
19. A comparison of different antibiotic regimens for the treatment of ... — www.cochranelibrary.com — https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009880.pub3/pdf/full/en
20. Antithrombotic and Thrombolytic Therapy for Valvular Disease — journal.chestnet.org — https://journal.chestnet.org/article/S0012-3692(12)60132-9/fulltext
21. Safety and Effectiveness of Edwards Lifesciences SAPIEN XTTM ... — cdn.clinicaltrials.gov — https://cdn.clinicaltrials.gov/large-docs/57/NCT03314857/Prot_SAP_000.pdf
22. Native valve, prosthetic valve, and cardiac device-related infective endocarditis: A review and update on current innovative diagnostic and therapeutic strategies — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC9574252
23. Methicillin-Resistant Staphylococcus aureus Prosthetic Valve Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6431130
24. Contemporary Features and Management of Endocarditis - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10572623

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.